Business

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 14, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.

articleAdicet Bio, Inc.May 14, 20261/company/adicet-bio-inc/news/adicet-bio-to-participate-in-fireside-chat-at-jefferies-global-healthcare-conference
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

About this update from Adicet Bio, Inc.

[{"type":"text","content":"REDWOOD CITY, Calif., May 14, 2026--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.","length":425,"tagName":"p"},{"type":"text","content":"Details of the event are as follows:Date: Thursday, June 4, 2026Time: 7:35a.m. ET","length":83,"tagName":"p"},{"type":"text","content":"The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.","length":193,"tagName":"p"},{"type":"text","content":"About Adicet Bio, Inc.","length":22,"tagName":"p"},{"type":"text","content":"Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.","length":414,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260514519453/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Adicet Bio., Inc. Investor and Media Contacts","length":46,"tagName":"p"},{"type":"text","content":"Anne [email protected]","length":37,"tagName":"p"},{"type":"text","content":"Penelope BelnapPrecision [email protected]","length":60,"tagName":"p"}]

More updates from Adicet Bio, Inc.

Adicet Bio, Inc.Jefferies Global Healthcare Conferenceautoimmune diseasesAdicet BioBUSINESS WIREbiotechnology company